文献速递白血病淋巴瘤浆细胞疾病

双特异性抗体引导T细胞靶向血液系统恶性肿瘤

Redirecting T cells to hematological malignancies with bispecific antibodies.
PubMed 文献 · Blood · 2017-11-08

本文综述双特异性抗体(BsAb)引导T细胞治疗复发/难治性血液系统恶性肿瘤的临床研究与疗效改进策略。博纳吐单抗(blinatumomab)作为最成功的BsAb,单药在急性淋巴细胞白血病中显示强效抗肿瘤活性并获美国FDA批准,但中位缓解持续时间不足1年。BsAb领域正扩展至急性髓系白血病和多发性骨髓瘤。

要点

  • 博纳吐单抗是靶向CD19和CD3的双特异性T细胞衔接器,单药在急性淋巴细胞白血病中显示强效抗肿瘤活性并获FDA批准。
  • 博纳吐单抗诱导的缓解通常短暂,中位缓解持续时间不足1年。
  • BsAb为现成产品,易于规模化生产,不同于过继T细胞疗法。

核心结论

  • 博纳吐单抗是迄今为止最成功的双特异性抗体,单药在急性淋巴细胞白血病中显示强效抗肿瘤活性并获美国FDA批准,但诱导的缓解通常短暂,中位缓解持续时间不足1年。

研究设计与样本

  • 本文为综述,聚焦于已开展的临床研究及提高双特异性抗体疗效的策略。

主要发现

  • 博纳吐单抗由两个单链可变区片段组成,分别特异性结合B细胞恶性肿瘤上的CD19和几乎所有T细胞上表达的CD3。
  • 博纳吐单抗单药在急性淋巴细胞白血病中显示强效抗肿瘤活性。
  • 博纳吐单抗诱导的缓解通常短暂,中位缓解持续时间不足1年。
  • 双特异性抗体的临床前和临床研究已涵盖B细胞来源的淋巴母细胞白血病和淋巴瘤、急性髓系白血病以及多发性骨髓瘤。

局限性

  • 博纳吐单抗诱导的缓解通常短暂,中位缓解持续时间不足1年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this need, because it does not rely on the cytotoxic mechanism of conventional therapies. Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an "off-the-shelf" product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell engager blinatumomab has emerged as the most successful BsAb to date. It consists of 2 single-chain variable fragments specific for CD19 present on B-cell malignancies and CD3 expressed on almost all T cells. Blinatumomab has shown potent antitumor activity as a single agent, particularly for acute lymphoblastic leukemia, resulting in its US Food and Drug Administration approval. However, although successful in inducing remissions, these are normally short-lived, with median response durations of <1 year. Nevertheless, the success of blinatumomab has reinvigorated the BsAb field, which is bustling with preclinical and clinical studies for not only B-cell-derived lymphoblastic leukemia and lymphoma but also acute myeloid leukemia and multiple myeloma. Here, we will review the successes and challenges of T-cell-targeted BsAbs for the immunotherapy of hematological malignancies with special focus on conducted clinical studies and strategies to improve their efficacy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Velasquez MP, Bonifant CL, Gottschalk S, et al. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2017. PMID: 29118005. doi:10.1182/blood-2017-06-741058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。